- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00606333
Comparison of the Conor Sirolimus-eluting Coronary Stent to the Taxus Liberte Paclitaxel-eluting Coronary Stent in the Treatment of Coronary Artery Lesions (NEVO RES-I)
A Randomized, Multi-Center, Single-Blind Comparison of the Conor Cobalt Chromium Reservoir Based Stent With Sirolimus Elution Versus the TAXUS Liberte Paclitaxel-eluting Coronary Stent System in De Novo Native Coronary Artery Lesions
The purpose of this study is to evaluate the safety and effectiveness of the Conor Sirolimus-eluting Coronary Stent System in the treatment of coronary artery disease (a single atherosclerotic lesion) in native coronary arteries. The study will evaluate the outcomes of a new drug-eluting stent compared to an approved drug-eluting stent.
While Cordis made a business decision to no longer pursue NEVO™ development and commercialization, the patients will be followed up as per protocol. This includes performing all protocol required follow-up visits and the collection and reporting of all safety information.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Restenosis remains a frequent cause of late failure following successful coronary angioplasty occurring in an estimated 20-40% of procedures performed. Coronary stents provide mechanical scaffolding that helps reduce restenosis by limiting the extent of elastic recoil and late vascular remodeling. Despite improvements over balloon angioplasty alone, restenosis following coronary stenting procedures has been cited to occur in 20-40% of cases and is primarily a result of neointimal hyperplasia. Thus, stents which are capable of delivering drugs to limit neointimal hyperplasia, in addition to providing mechanical support at the area of the lesion, have been developed to further limit the extent of restenosis following coronary stenting. There are several pharmacologic agents approved for use with drug-eluting stents.Two drugs have been widely studied in controlled clinical trials and real-world patient populations, sirolimus and paclitaxel.
This study will evaluate a new sirolimus-eluting cobalt chromium coronary stent system compared to an approved paclitaxel-eluting coronary stent system in the treatment of single de novo coronary lesions in native coronary arteries. Subjects meeting qualification will be randomized in a 1:1 fashion to treatment with the Conor sirolimus-eluting coronary stent or to treatment with an approved paclitaxel-eluting coronary stent. All subjects will undergo angiographic follow-up at six months and complete clinical follow-up for a period of five years.
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
-
Sao Paulo, Brasil, 04012-909
- Instituto Dante Pazzanese de Cardiologia
-
-
-
-
Auckland
-
Epsom, Auckland, New Zealand
- Mercy Angiography Unit
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- 18 years of age or older
- Eligible for percutaneous coronary intervention and coronary artery bypass graft surgery.
- Diagnosis of stable or unstable angina or silent ischemia
- Left ventricular ejection fraction >30%
- The subject requires treatment of a single de novo lesion in a native coronary artery.
- Lesion to be treated is less than or equal to 28 mm in length in a vessel that is 2.5-3.5mm diameter.
- The target lesion diameter stenosis is >50% and <100% by visual estimate.
- The target lesion is a minimum of 10 mm distance from any previously treated segment of the target vessel.
- The subject understands the study requirements, is willing to comply with all study procedures and has provided written informed consent.
Exclusion Criteria:
- The subject has undergone coronary revascularization to any vessel within 30 days.
- The subject has undergone target vessel revascularization within 6 months.
- Treatment of more than one qualifying lesion is required at the time of enrollment, or is planned within 30 days following enrollment.
- The subject has known sensitivity to sirolimus, paclitaxel, the polymeric matrices, stainless steel or cobalt chromium.
- There is planned treatment of the target lesion with any device other than the pre-dilatation balloon angioplasty catheter.
- The subject had a myocardial infarction within 72 hours, or presents with CK elevation > 2 times upper limit normal associated with elevated CK-MB.
- The subject is in cardiogenic shock.
- The subject had a cerebrovascular accident within the past 6 months.
- The subject has acute or chronic renal dysfunction (defined as creatinine >2.0 mg/dl).
- The subject has a contraindication to aspirin or clopidogrel.
- The subject has thrombocytopenia (platelet count < 100,000/mm3.
- The subject has had active gastrointestinal bleeding within the past 3 months.
- The subject has a known bleeding or hypercoagulable disorder.
- The subject has had prior anaphylactoid reaction to contrast agents or has contrast sensitivity that cannot be controlled with pre-medication.
- The subject is currently taking immunosuppressant therapy.
- The subject is currently, or has been treated wtih either Rapamune or paclitaxel within 12 months of the procedure.
- The subject is a female with a positive pregnancy test or is lactating.
- The subject has an active infection.
- The subject has co-morbidities that could interfere wtih completion of study procedures, or life expectancy less than 24 months.
- The subject is participating in another investigational drug or device trial that has not completed the primary endpoint or would interfere with the endpoints of this study.
Angiographic Exclusion Criteria
- Left main disease >50% diameter stenosis.
- The target lesion is ostial.
- The target lesion or target vessel are severely calcified.
- The target lesion involves a bifurcation with diseased branch vessel greater than or equal to 2.0 mm that would require intervention or protection.
- The target lesion has TIMI o or TIMI I flow.
- Angiographic evidence of thrombus.
- The target vessel has had prior stent placement.
- The patient has had prior coronary brachytherapy.
- There is angiographic restenosis of any previously treated segment of the target vessel, or atherosclerotic area wtih >50% diameter stenosis outside of the target lesion.
- The subject has undergone prior CABG.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Investigational arm
Subjects randomized to treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
|
Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques.
Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System.
Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
|
Aktiv komparator: Control Arm
Subjects randomized to treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System.
|
Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques.
Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System.
Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Angiographic endpoint of in-stent late lumen loss as measured by QCA.
Tidsramme: 6 months
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Target Lesion Failure defined as cardiac death that cannot be clearly attributed to a non-cardiac event or non-target vessel, target vessel related myocardial infarction or clinically driven target lesion revascularization.
Tidsramme: hospital discharge, 30 days, 6 months and annually through five years.
|
hospital discharge, 30 days, 6 months and annually through five years.
|
Target Vessel Failure defined as any myocardial infarction or cardiac death that cannot be attributed to a non-target vessel or any target vessel revascularization.
Tidsramme: Hospital discharge, 30 days, 6 months and annually through five years
|
Hospital discharge, 30 days, 6 months and annually through five years
|
Major Adverse Cardiac Events defined as an adjudicated composite of death, emergent coronary artery bypass graft surgery, target lesion revascularization, or new myocardial infarction.
Tidsramme: Hospital discharge, 30 days, 6 months and annually through five years
|
Hospital discharge, 30 days, 6 months and annually through five years
|
Incidence of stent thrombosis
Tidsramme: Hospital discharge, 30 days, 6 months and annually through five years
|
Hospital discharge, 30 days, 6 months and annually through five years
|
Incidence of target lesion revascularization and target vessel revascularization.
Tidsramme: Hospital discharge, 30 days, 6 months and annually through five years
|
Hospital discharge, 30 days, 6 months and annually through five years
|
Device Success
Tidsramme: Procedural
|
Procedural
|
Lesion success
Tidsramme: Procedural
|
Procedural
|
Procedure Success
Tidsramme: Hospital Discharge
|
Hospital Discharge
|
Angiographic in-stent and in-segment binary restenosis.
Tidsramme: 6 months
|
6 months
|
In-stent minimum lumen diameter
Tidsramme: 6 months
|
6 months
|
Percent volume obstruction of the stent by intravascular ultrasound evaluation
Tidsramme: 6 months
|
6 months
|
Patient reported outcomes as measured by three standardized quality of life surveys.
Tidsramme: Baseline, 30 days, 6 months and 12 months
|
Baseline, 30 days, 6 months and 12 months
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: John Ormiston, MB ChM, Mercy Angiography Unit
- Hovedetterforsker: Alexandre Abizaid, MD. PhD, Instituto Dante Pazzanese de Cardiologia
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Ormiston JA, Abizaid A, Spertus J, Fajadet J, Mauri L, Schofer J, Verheye S, Dens J, Thuesen L, Dubois C, Hoffmann R, Wijns W, Fitzgerald PJ, Popma JJ, Macours N, Cebrian A, Stoll HP, Rogers C, Spaulding C; NEVO ResElution-I Investigators. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberte paclitaxel-eluting stent in de novo native coronary artery lesions. Circ Cardiovasc Interv. 2010 Dec;3(6):556-64. doi: 10.1161/CIRCINTERVENTIONS.110.946426. Epub 2010 Nov 9. Erratum In: Circ Cardiovasc Interv. 2011 Feb 1;4(1):e4.
- Otake H, Honda Y, Courtney BK, Shimohama T, Ako J, Waseda K, Macours N, Rogers C, Popma JJ, Abizaid A, Ormiston JA, Spaulding C, Cohen SA, Fitzgerald PJ. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberte stents in de novo native coronary artery lesions. Circ Cardiovasc Interv. 2011 Apr 1;4(2):146-54. doi: 10.1161/CIRCINTERVENTIONS.110.957175. Epub 2011 Mar 8.
- Abizaid A, Ormiston JA, Fajadet J, Mauri L, Schofer J, Verheye S, Dens J, Thuesen L, Macours N, Qureshi AC, Spaulding C; NEVO ResElution-I Investigators. Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberte paclitaxel-eluting stent in de novo native coronary artery lesions. EuroIntervention. 2013 Oct;9(6):721-9. doi: 10.4244/EIJV9I6A116.
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hjertesykdommer
- Kardiovaskulære sykdommer
- Vaskulære sykdommer
- Arteriosklerose
- Arterielle okklusive sykdommer
- Koronar sykdom
- Koronararteriesykdom
- Myokardiskemi
- Aterosklerose
- Fysiologiske effekter av legemidler
- Molekylære mekanismer for farmakologisk virkning
- Anti-infeksjonsmidler
- Antineoplastiske midler
- Immunsuppressive midler
- Immunologiske faktorer
- Tubulin modulatorer
- Antimitotiske midler
- Mitosemodulatorer
- Antineoplastiske midler, fytogene
- Antibakterielle midler
- Antibiotika, antineoplastisk
- Antifungale midler
- Paklitaksel
- Albuminbundet paklitaksel
- Sirolimus
Andre studie-ID-numre
- CP-06
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Koronar aterosklerose
-
IRCCS Policlinico S. DonatoRekrutteringAnomalous aortic origin of the coronary artery (AAOCA)Italia
-
Medtronic CardiovascularFullførtArteriosclerosis of coronary artery bypass graftCanada, Forente stater
-
Lawson Health Research InstituteFullførtArteriosclerosis of arterial coronary artery bypass graftCanada
-
Deutsches Herzzentrum MuenchenFullførtArteriosclerosis of arterial coronary artery bypass graftTyskland
-
Izmir Bakircay UniversityFullførtMyocardial Bridge of Coronary ArteryTyrkia
-
William Beaumont HospitalsFullførtKoronararteriesykdom | Arteriosclerosis of coronary artery bypass graftForente stater
-
ITAB - Institute for Advanced Biomedical TechnologiesAzienda Ospedaliero, Universitaria Ospedali RiunitiFullførtMyocardial Bridge of Coronary ArteryItalia
Kliniske studier på NEVO™ Sirolimus-eluting Coronary Stent System
-
Biotronik AGFullførtKoronararteriesykdomRomania
-
Genoss Co., Ltd.RekrutteringKoronararteriesykdom | Medikamentavgivende stentKorea, Republikken
-
Concept Medical Inc.Aktiv, ikke rekrutterendeKoronararteriesykdom | Diabetes | Akutt koronarsyndromSveits, Australia, Korea, Republikken, Frankrike, Belgia, Nederland, Storbritannia, India, Østerrike, Bangladesh, Brasil, Tsjekkia, Tyskland, Irland, Italia, Malaysia, Mexico, Polen, Singapore, Sverige, Taiwan
-
Meril Life Sciences Pvt. Ltd.Lifecare Institute of Medical Sciences and Research Ahmedabad Gujarat...Fullført
-
Instituto Nacional de Cardiologia Ignacio ChavezRekrutteringKoronararteriesykdom | Sukkersyke | Akutt koronarsyndromMexico
-
Advanced MedTech Solutions Pvt. Ltd.Har ikke rekruttert ennåKoronararteriesykdom | Koronar stentimplantasjon | De Novo stenoselesjon
-
Conor MedsystemsAvsluttet
-
Meril Life Sciences Pvt. Ltd.Ukjent
-
Seung-Jung ParkCardioVascular Research Foundation, Korea; Biotronik Korea Co., LtdFullførtKoronararteriesykdom | Angioplastikk, Transluminal, Perkutan koronarKorea, Republikken